CDK4/6 inhibitors are standard-of-care treatment of breast cancer, however resistance is common. Here, the authors analyse real world multi-omics data from 400 breast cancer patients and identify bifurcated evolutionary trajectories associated with ER independent resistance.
- Zhengyan Kan
- Ji Wen
- Jadwiga Bienkowska
